New Reference: Tafasitamab with Rituximab/Lenalidomide for Rel/Ref Follicular Lymphoma

The addition of tafasitamab to lenalidomide and rituximab significantly improved progression-free survival and overall response rate compared to the placebo group. The treatment was well-tolerated with manageable side effects, positioning it as a potential new standard of care for relapsed or refractory follicular lymphoma.

Study

Phase 3, double-blind, randomised, placebo-controlled trial [inMIND]

Relapsed or refractory follicular lymphoma after at least one previous line of systemic therapy

Tafasitamab+lenalidomide+rituximab (n=273) vs placebo+lenalidomide+rituximab (n=275)

Efficacy

ORR: 84% vs 72% (tafasitamab vs. placebo) (OR 2.0 [1.30-3.02])

mPFS: 22.4 mos vs 13.9 mos (HR 0.43 [0.32-0.58])

mDoR: 21.2 mos vs 13.6 mos (HR 0.47 [0.33-0.68])

Safety

Grade >=3 AEs: Neutropenia (40% vs 38%), pneumonia (8% vs. 5%)

Treatment discontinuations: 11% vs 7%

Lancet 2026;407:133–46

Sehn LH, Hubel K, Luminari S Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial

http://doi.org/10.1016/S0140-6736(25)01778-7

Reviewed by Ulas D. Bayraktar, MD on Jan 21, 2026

Back to top Drag